Searched for
PREVNAR
Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...- Pfizer agrees to lower prescription drug costs for Medicaid in a deal with TrumpPfizer agreed to lower drug costs and invest $70 billion in U.S. manufacturing following a deal with the Trump administration. The drugmake...
- Pfizer Q1 Results: Co lifts profit view on cost cuts, smaller drop in PaxlovidPfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cu...
- BE's pediatric pneumonia jab gets CDSCO expert panel approvalThe BE's pneumococcal conjugate vaccine (PCV) can be administered to infants at 6, 10 and 14 weeks of age. Streptococcus pneumoniae infecti...
- Indian vaccine makers gaining wider market share in industryAccording to a TOI report, indigenously-manufactured vaccines have started to capture share from MNCs in certain diseases even as the Rs 3,...
- Pfizer study shows COVID-19 booster can be co-administered with pneumonia shotThe data provides evidence supporting the potential to administer pneumonia shot, PREVNAR 20, and the company's COVID-19 vaccine at the sam...
- Hold Pfizer, target price Rs 4,665: Anand RathiThe pharma major launched its patented product, Zavicefta, in India in H1 FY20. This was the first anti-infective drug launched by Pfizer i...
- Centrum maintains buy on Pfizer, target price Rs 5,000Shares of Pfizer closed at Rs 4,128, up 2.5%.
- Analyst Calls: Pfizer, SBI, JSW Energy, EILCentrum maintained its ‘buy’ rating on Pfizer with a target price of Rs 5,000.
- Gates foundation interested in preventing infectious diseases: Keith Klugman, Bill and Melinda Gates FoundationKlugman speaks to ET Pharma about how the government can succeed in combating pneumonia and related threats of antibiotic resistance with t...
- MSF and Pfizer battle over patent application for life-saving pneumonia vaccineMSF filed declarations at the Delhi patent office to point out that Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) was obvious a...
- Pfizer may leverage European approval to pneumonia vaccine in Indian marketNew York-headquartered pharmaceutical giant is likely to leverage its latest European approval for multi-dose vials of pneumococcal vaccine...
- Big Pharma plans to tap healthy ageing business; to identify and support age-related diseases and their preventionThese efforts may be particularly relevant for countries like India and China, which are projected to have the world’s largest elderly popu...
- Pfizer’s growth outlook seen strongThe Pfizer stock has offered better returns to investors than the Bombay Stock Exchange’s (BSE) benchmark index, the Sensex, over the past ...
- Wyeth seeks to include Prevnar in immunisation programmePharma major Wyeth (India) is in talks with the government to include its pneumococcal vaccine (PCV), Prevnar in the country’s national imm...
- Wyeth gets DCGI nod to resume trials of Prevnar 13Pharma firm Wyeth has been given the go-ahead by the country's drug regulator to resume clinical trials for its Prevnar 13 vaccine in India...
- Indian vaccine cos want a slice of US pieIndian vaccine makers are setting their sights on tapping the growing US market after the Obama administration committed $300 million for i...
- Pharma MNCs want to take a shot at India’s vaccine marketMultinational pharmaceutical companies are now increasingly looking at the Indian vaccine market in a big way. MSD Pharmaceuticals, GlaxoSm...
- Novartis may route new drugs through subsidiaryContrary to investor expectations, Novartis may launch some of its new-patented drugs in India through its wholly-owned subsidiary.
- Local pharma hits patent wall, new drug launches slideThis one’s a pop out for pharma. Revenues from new product launches in the pharma sector fell 48% to Rs 224.2 crore in ’05.
Load More
